Condition: Refractory Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia · Sponsor: Stanford University
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
This description comes directly from the study's public registry record.
Woo In (Yustina) Cho · 650-721-2443 · wooin@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06561152